BACKGROUND: Ablation has become an important option for treatment of ventricular tachycardia (VT). The influence of procedure duration on outcomes remains unexamined. OBJECTIVE: The purpose of this study was to determine the influence of procedure duration on outcomes and complications over an 8-year period METHODS: Patients referred for scar-mediated VT ablation from 2004 to 2011 were retrospectively analyzed. Procedure duration was defined as the time from the insertion of catheters through the femoral vein to the time of their withdrawal. Procedure duration was analyzed in relationship with baseline and intraoperative covariates, acute procedural outcomes, complications, and 6-month clinical outcomes. RESULTS: One hundred forty-eight patients underwent VT ablation with mean procedure duration of 5.7 ± 1.8 hours. VT recurrence and survival at 6 months were 46% and 82%, respectively, and were not associated with procedure duration. Hospital mortality increased with intraoperative intraaortic balloon pump insertion (adjusted odds ratio [OR] 13.7, 95% confidence interval [CI] 2.35-79.94, P = .004) and was improved with successful ablation of the clinical VT as a procedural end-point (adjusted OR 0.13, 95% Cl 0.03-0.54, P = .005). The association between procedure duration and hospital mortality remained after adjusting for significant baseline variables (adjusted OR 1.75, 95% CI 1.14-2.68, P = .0098) and intraoperative variables (adjusted OR 1.6, 95% CI 1.12-2.29, P = .0104). CONCLUSION: Hospital mortality was significantly increased by unsuccessful clinical VT ablation as a procedural end-point and intraoperative intraaortic balloon pump insertion. However, after adjusting for significant baseline and intraoperative covariates, procedure duration still was associated with increased hospital mortality. Procedure duration had no impact on VT recurrence and survival at 6 months.
BACKGROUND: Ablation has become an important option for treatment of ventricular tachycardia (VT). The influence of procedure duration on outcomes remains unexamined. OBJECTIVE: The purpose of this study was to determine the influence of procedure duration on outcomes and complications over an 8-year period METHODS:Patients referred for scar-mediated VT ablation from 2004 to 2011 were retrospectively analyzed. Procedure duration was defined as the time from the insertion of catheters through the femoral vein to the time of their withdrawal. Procedure duration was analyzed in relationship with baseline and intraoperative covariates, acute procedural outcomes, complications, and 6-month clinical outcomes. RESULTS: One hundred forty-eight patients underwent VT ablation with mean procedure duration of 5.7 ± 1.8 hours. VT recurrence and survival at 6 months were 46% and 82%, respectively, and were not associated with procedure duration. Hospital mortality increased with intraoperative intraaortic balloon pump insertion (adjusted odds ratio [OR] 13.7, 95% confidence interval [CI] 2.35-79.94, P = .004) and was improved with successful ablation of the clinical VT as a procedural end-point (adjusted OR 0.13, 95% Cl 0.03-0.54, P = .005). The association between procedure duration and hospital mortality remained after adjusting for significant baseline variables (adjusted OR 1.75, 95% CI 1.14-2.68, P = .0098) and intraoperative variables (adjusted OR 1.6, 95% CI 1.12-2.29, P = .0104). CONCLUSION: Hospital mortality was significantly increased by unsuccessful clinical VT ablation as a procedural end-point and intraoperative intraaortic balloon pump insertion. However, after adjusting for significant baseline and intraoperative covariates, procedure duration still was associated with increased hospital mortality. Procedure duration had no impact on VT recurrence and survival at 6 months.
Authors: David A Cesario; Marmar Vaseghi; Noel G Boyle; Michael C Fishbein; Miguel Valderrábano; Calambur Narasimhan; Isaac Wiener; Kalyanam Shivkumar Journal: Heart Rhythm Date: 2006-01 Impact factor: 6.343
Authors: Etienne M Aliot; William G Stevenson; Jesus Ma Almendral-Garrote; Frank Bogun; C Hugh Calkins; Etienne Delacretaz; Paolo Della Bella; Gerhard Hindricks; Pierre Jaïs; Mark E Josephson; Josef Kautzner; G Neal Kay; Karl-Heinz Kuck; Bruce B Lerman; Francis Marchlinski; Vivek Reddy; Martin-Jan Schalij; Richard Schilling; Kyoko Soejima; David Wilber Journal: Europace Date: 2009-05-14 Impact factor: 5.214
Authors: Elad Anter; Mathew D Hutchinson; Rajat Deo; Haris M Haqqani; David J Callans; Edward P Gerstenfeld; Fermin C Garcia; Rupa Bala; David Lin; Michael P Riley; Harold I Litt; Joseph Y Woo; Michael A Acker; Wilson Y Szeto; Erica S Zado; Francis E Marchlinski; Sanjay Dixit Journal: Circ Arrhythm Electrophysiol Date: 2011-06-14
Authors: Roderick Tung; Shiro Nakahara; Giuseppe Maccabelli; Eric Buch; Isaac Wiener; Noel G Boyle; Corrado Carbucicchio; Paolo Della Bella; Kalyanam Shivkumar Journal: J Cardiovasc Electrophysiol Date: 2011-01
Authors: Miki Yokokawa; Benoit Desjardins; Thomas Crawford; Eric Good; Fred Morady; Frank Bogun Journal: J Am Coll Cardiol Date: 2012-11-01 Impact factor: 24.094
Authors: Nilesh Mathuria; Geru Wu; Francia Rojas-Delgado; Mossaab Shuraih; Mehdi Razavi; Andrew Civitello; Leo Simpson; Guilherme Silva; Suwei Wang; MacArthur Elayda; Bharat Kantharia; Steve Singh; O H Frazier; Jie Cheng Journal: J Interv Card Electrophysiol Date: 2016-08-06 Impact factor: 1.900